本报讯(记者梁傲男)近年来，肥胖问题日益凸显，"体重管理"已成为备受关注的"破圈热词"。 在此背景下，GLP-1类药物因其在减重方面的显著效果而广受关注，为科学体重管理提供了全新路径。 然而，目前主流GLP-1类药物仍以注射剂型为主，对使用环境和储存条件要求较高，或者对于饮食有严 格要求，一定程度上限制了其在超重及肥胖人群中的广泛应用。临床与患者对"非注射""高依从性"治疗 方案的需求日益迫切。 近日，跨国药企礼来公司公布其口服小分子GLP-1RA药物orforglipron成人肥胖患者关键3期研究Attain-1 的顶线数据。作为一款每日一次、无须控制饮食的创新口服治疗方案，orforglipron展现出显著的减重效 果，最高剂量组平均体重减少12.4kg，体重减轻≥15%的参与者比例达39.6%每个剂量组在主要终点和所 有关键次要终点上，均实现了具有统计学意义的改善。试验展现出的积极结果，表明orforglipron有望为 超重或患者提供更加便捷的治疗选择。 据了解，Attain-1是一项全球性的3期研究，共纳入3127名参与者，并广泛覆盖中国参与者，旨在比较 orforglipron(6mg、12mg和 ...

Core Viewpoint - Watson Bio (300142.SZ) has signed an amendment to its exclusive sublicense agreement with Notitia Biotechnologies Company to enhance its market competitiveness and expand its core microbiome therapy in the field of precise micro-ecological health and functional nutrition intervention [1] Group 1: Agreement Details - The amendment allows Watson Bio to exclusively develop, manufacture, and commercialize core microbiome analysis, microbiome-targeted transplantation, and nutritional formula technologies in mainland China, Hong Kong, and Macau for non-patient populations [1] - This agreement is based on the upstream licensing agreement that Notitia has with Rutgers University in New Jersey, USA [1] Group 2: Strategic Implications - The signing of this amendment signifies a dual-track layout for the company, combining "disease treatment intervention" with "chronic disease prevention and health nutrition" [1] - The initiative aligns with national policies on non-drug interventions and emphasizes the importance of chronic disease nutrition and prevention strategies [1] Group 3: Market Positioning - The company aims to provide a comprehensive health solution that covers in-hospital treatment, out-of-hospital management, and multi-scenario interventions [1] - This move is expected to integrate existing clinical pathways and underlying technology platform construction, offering diverse product forms to address sub-health and high-risk chronic disease populations [1]

Core Viewpoint - The "2025 Chronic Disease Prevention and Control Quality Science Popularization Promotion Action" was launched to enhance public health literacy and promote chronic disease prevention knowledge in China [1][2] Group 1: Action Overview - The initiative is a collaboration between the Chinese Center for Disease Control and Prevention (CDC) and People's Health, aiming to explore innovative paths for chronic disease prevention and control [1] - The action has received over 23,000 pieces of science popularization content, including articles, infographics, and short videos, with 1,600 quality works highlighted, reaching over 30 million readers [2] Group 2: Strategies and Goals - Emphasis on a multi-faceted approach to chronic disease prevention, including strengthening health education personnel, incentivizing healthcare workers, and increasing public awareness of personal health responsibility [2] - The new year's action aims to engage experts and doctors in disseminating chronic disease prevention knowledge [2] Group 3: Technological Integration - The "Healthy City" data intelligence solution was introduced to assist local governments in building health cities, focusing on chronic disease intervention and health science popularization [3] Group 4: Expert Contributions - Medical professionals shared experiences on transforming complex medical knowledge into accessible science popularization content, highlighting the importance of effective communication in healthcare [4] - The initiative includes the appointment of 20 science popularization authors and 9 experts to support the action, enhancing the quality of health education [5] Group 5: Patient-Centric Approaches - The need for improved health science education to aid chronic disease management is emphasized, particularly in the context of aging populations and the rising prevalence of chronic diseases [6]